Member Info for EmeraldCarrots

That WILL be interesting.

Other major pharma C's will follow suit IMHO.

https://www.lse.co.uk/rns/CLBX/msa-with-global-pharmaceutical-company-egbtxodxy71zuq7.html

And we have Myriad genetics collaborating with us since last August. What will that bring as far as deals go?

They don't either buy a load of Parsortix machines, do a deal with an existing Company that has spare capacity (good luck with that one!), or do a similar deal with Cellbxhealth? Doing a deal whereby Cellbxhealth do the analysing makes the most sense. Form an orderly queue..................

All IMHO.

Cellbxhealth have the Parsortix machine and it can catch live, intact, uncontaminated CTC's. How are they going to compete without having it too??????????????????????????? What are they going to do? LOL!!!

So this agreement confirms Astrazeneca believe CTC's are worth analysing (sets them up to pay less for the service no doubt). The question is how many drug trials do they have in mind? 2, 10, 20, more????? Every one that involves metastasized cancer I would have thought!!!!!!! After all you can see what affect the drug has on the CTC's, valuable information that everyone wants, is that NOT true??? And if that is what they want the other majors will want similar!

All IMHO.

In cancer drug trials where the cancer is suspected of, or is spreading then the order book will blast off into space. It seems to me the circulating tumour cells (CTC's) in ALL cancer drug trials where the cancer has, or is suspected of metastasizing (spreading) should be analysed before, during and after treatment to see how they react. Seems totally obvious to me. Could nit be more obvious.

All IMHO.

"Our results indicate that AXL-mRNA overexpression in CTC fractions deserves to be further evaluated through larger clinical studies as a potential biomarker for anti-AXL targeted therapies in NSCLC.".

====================

Conclusion is a larger scale cancer drug trial is warranted>>>>>>

Https://www.mdpi.com/2072-6694/18/11/1759

Around June 2026".

- Monday is 1st June. The sooner the better. We have been waiting long enough!

================================

FDA 510(k) submission for Genedrive® CYP2C19 currently anticipated around June 2026, pending completion of studies, with an expected 3-4 month review period post submission

Laying mines? At what point is the cease fire broken!!

Executive Officer mentioned he is attending in the last video brief. So are the likes of Immatics, who are doing some presentations and we are involved with the cancer drug trial they are doing which is at phase 3. Maybe there will be good news?

=======================

Just one of many potential massive money spinning deals Cellbxhealth are involved with.

https://www.asco.org/annual-meeting/program

Executive Officer mentioned he is attending in the last video brief. So are the likes of Immatics, who are doing some presentations and we are involved with the cancer drug trial they are doing which is at phase 3. Maybe there will be good news?

https://www.asco.org/annual-meeting/program

If you look at the chart you will see it is breaking out, and has been for several weeks.

Targeting an American air base they say was the source of US strikes on Iranian targets hours before.

https://edition.cnn.com/2026/05/28/world/live-news/iran-war-us-news

Https://edition.cnn.com/2026/05/27/world/live-news/iran-war-us-news?t=1779924854022

I'm still waiting for the expected RNS flagged in the RNS of 11th May!

All IMHO.

Hopefully there will be more focus on selling the 2 machines we already have. I appreciate the path to breaking into the EU and USA markets if difficult. The UK path was, and in fact still is what with having to deal with NICE. There are 27 Countries in the EU. What progress has been made here? Not a lot? I suspect Mr Nugent will be focused on how we can get far better progress. The neonatal wards in all these countries are dishing out antibiotics with the possibility the drug will render the baby deaf for heavens sake! They must want our machine to do the test if they even knew about it!

All IMHO.

"The US Food and Drug Administration (FDA) has informed AstraZeneca that it will extend the Prescription Drug User Fee Act (PDUFA) date to review additional data requested to support the New Drug Application (NDA) for camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) for the 1st-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumours have an emergent ESR1 mutation.".

============================

How do you test for ESR1 mutation?

Some doctors might use a tissue biopsy, or sample of the metastatic breast cancer tissue, to test for an ESR1 mutation using a technology called next-generation sequencing. ASCO recommends liquid biopsy as a more sensitive test, though. Some doctors might order both blood and tissue tests."

============================

Potential massive order is it not???????

============================

The sp here is utterly ridiculous if you ask me. I am reading time and time again that liquid biopsies are needed, and the market is massively expanding. Cellbxhealth are one of the top, it nit the top Company is this field FFS!!!!!!!!!!!!!!!!!!!

No wonder we are waiting for confirmation of a deal with a top 10 pharma Co. who is negotiating with us NOW!!!!!!!!!!!!!!!!!!!

HOW MANY MORE??????????????????????

All IMHO.

"The US Food and Drug Administration (FDA) has informed AstraZeneca that it will extend the Prescription Drug User Fee Act (PDUFA) date to review additional data requested to support the New Drug Application (NDA) for camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) for the 1st-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumours have an emergent ESR1 mutation.".

============================

How do you test for ESR1 mutation?

Some doctors might use a tissue biopsy, or sample of the metastatic breast cancer tissue, to test for an ESR1 mutation using a technology called next-generation sequencing. ASCO recommends liquid biopsy as a more sensitive test, though. Some doctors might order both blood and tissue tests."

============================

Potential massive order is it not???????

It's quite incredible. Sp seems undervalued by an absolute minimum of 50% now and a maximum of multiples of that! No wonder we are about 50% higher than a week or so ago. Still only half the 4p......... in fact less than half the 4p! Currently 1.8p to buy!

All IMHO.